12/25
11:03 pm
livn
LivaNova PLC (NASDAQ: LIVN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
LivaNova PLC (NASDAQ: LIVN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
12/19
02:41 pm
livn
How stimulating the body's largest nerve may relieve severe depression [CNN]
Low
Report
How stimulating the body's largest nerve may relieve severe depression [CNN]
12/19
01:11 pm
livn
For those with treatment-resistant depression, vagus nerve stimulation may be an answer, studies suggest [CNN]
Low
Report
For those with treatment-resistant depression, vagus nerve stimulation may be an answer, studies suggest [CNN]
12/18
08:33 am
livn
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression [Yahoo! Finance]
Medium
Report
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression [Yahoo! Finance]
12/18
08:30 am
livn
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
Low
Report
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
12/17
11:03 pm
livn
LivaNova PLC (NASDAQ: LIVN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Medium
Report
LivaNova PLC (NASDAQ: LIVN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
12/5
09:25 am
livn
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting [Yahoo! Finance]
Low
Report
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting [Yahoo! Finance]
12/5
09:00 am
livn
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting
Low
Report
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting
12/2
11:32 am
livn
Neurava Announces Strategic Additions to Board of Directors: Medical Device Veteran Daniel Moore and Jed Kay, an Elevate Ventures' Operating Partner, Bring Unmatched Expertise [Yahoo! Finance]
Low
Report
Neurava Announces Strategic Additions to Board of Directors: Medical Device Veteran Daniel Moore and Jed Kay, an Elevate Ventures' Operating Partner, Bring Unmatched Expertise [Yahoo! Finance]
11/28
11:49 am
livn
LivaNova PLC's (NASDAQ:LIVN) Stock Has Shown A Decent Performance: Have Financials A Role To Play? [Yahoo! Finance]
Low
Report
LivaNova PLC's (NASDAQ:LIVN) Stock Has Shown A Decent Performance: Have Financials A Role To Play? [Yahoo! Finance]
11/25
08:05 am
livn
LivaNova PLC (NASDAQ: LIVN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $75.00 price target on the stock.
Low
Report
LivaNova PLC (NASDAQ: LIVN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $75.00 price target on the stock.
11/18
09:34 am
livn
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint [Yahoo! Finance]
Low
Report
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint [Yahoo! Finance]
11/16
03:06 am
livn
LivaNova PLC (NASDAQ: LIVN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
LivaNova PLC (NASDAQ: LIVN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/14
09:00 am
livn
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
Low
Report
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
11/13
05:59 am
livn
Goldman Sachs Says Improving Growth Could Propel These 2 Stocks Higher [Yahoo! Finance]
Low
Report
Goldman Sachs Says Improving Growth Could Propel These 2 Stocks Higher [Yahoo! Finance]
11/12
11:06 am
livn
LivaNova PLC (NASDAQ: LIVN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $75.00 price target on the stock.
Low
Report
LivaNova PLC (NASDAQ: LIVN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $75.00 price target on the stock.
11/12
05:39 am
livn
Shareholders Will Be Pleased With The Quality of LivaNova's (NASDAQ:LIVN) Earnings [Yahoo! Finance]
Low
Report
Shareholders Will Be Pleased With The Quality of LivaNova's (NASDAQ:LIVN) Earnings [Yahoo! Finance]
11/11
04:05 pm
livn
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
Low
Report
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
11/8
11:07 pm
livn
LivaNova PLC (NASDAQ: LIVN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Low
Report
LivaNova PLC (NASDAQ: LIVN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
11/7
01:42 pm
livn
LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock? [Yahoo! Finance]
Low
Report
LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock? [Yahoo! Finance]
11/7
11:47 am
livn
How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2% [Yahoo! Finance]
Low
Report
How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2% [Yahoo! Finance]
11/5
03:44 am
livn
Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development [Yahoo! Finance]
Medium
Report
Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development [Yahoo! Finance]
11/3
07:22 am
livn
Earnings Beat: LivaNova PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models [Yahoo! Finance]
Low
Report
Earnings Beat: LivaNova PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models [Yahoo! Finance]
10/31
10:42 am
livn
LivaNova PLC (NASDAQ: LIVN) had its price target lowered by analysts at Mizuho from $80.00 to $70.00. They now have an "outperform" rating on the stock.
Low
Report
LivaNova PLC (NASDAQ: LIVN) had its price target lowered by analysts at Mizuho from $80.00 to $70.00. They now have an "outperform" rating on the stock.
10/31
08:35 am
livn
LivaNova PLC (NASDAQ: LIVN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $75.00 price target on the stock.
Medium
Report
LivaNova PLC (NASDAQ: LIVN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $75.00 price target on the stock.